Recent Publications

  1. Abner EL, Kryscio RJ, Cooper GE, Fardo DW, Jicha GA, Mendiondo MS, Nelson PT, Smith CD, Van Eldik LJ, Wan L, Schmitt FA (2012) Mild cognitive impairment: statistical models of transition using longitudinal clinical data. Int J Alzheimers Dis 2012:291920.
  2. Andersen AH, Rayens WS, Liu Y, Smith CD (2012) Partial least squares for discrimination in fMRI data. Magn Reson Imaging 30:446-452.
  3. Barone E, Di Domenico F, Sultana R, Coccia R, Mancuso C, Perluigi M, Butterfield DA (2012) Heme oxygenase-1 posttranslational modifications in the brain of subjects with Alzheimer disease and mild cognitive impairment. Free Radic Biol Med 52:2292-2301.
  4. Barone E, Mancuso C, Di Domenico F, Sultana R, Murphy MP, Head E, Butterfield DA (2012) Biliverdin reductase-A: a novel drug target for atorvastatin in a dog pre-clinical model of Alzheimer disease. J Neurochem 120:135-146.
  5. Blonder LX, Pettigrew CL, Kryscio RJ (2012) Emotion recognition and marital satisfaction in stroke. Journal of clinical and experimental neuropsychology.
  6. Butterfield A, Dalle-Donne I (2012) Redox Proteomics. Antioxid Redox Signal.
  7. Butterfield DA, Perluigi M, Reed T, Muharib T, Hughes CP, Robinson RA, Sultana R (2012) Redox Proteomics in Selected Neurodegenerative Disorders: From Its Infancy to Future Applications. Antioxid Redox Signal.
  8. Caban-Holt A, Abner E, Kryscio RJ, Crowley JJ, Schmitt FA (2012) Age-expanded normative data for the ruff 2&7 selective attention test: evaluating cognition in older males. The Clinical neuropsychologist 26:751-768.
  9. Cenini G, Dowling AL, Beckett TL, Barone E, Mancuso C, Murphy MP, Levine H, 3rd, Lott IT, Schmitt FA, Butterfield DA, Head E (2012) Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome. Biochim Biophys Acta 1822:130-138.
  10. Counts SE, He B, Nadeem M, Wuu J, Scheff SW, Mufson EJ (2012) Hippocampal Drebrin Loss in Mild Cognitive Impairment. Neurodegener Dis.
  11. Di Domenico F, Casalena G, Jia J, Sultana R, Barone E, Cai J, Pierce WM, Cini C, Mancuso C, Perluigi M, Davis CM, Alkayed NJ, Butterfield DA (2012) Sex differences in brain proteomes of neuron-specific STAT3-null mice after cerebral ischemia/reperfusion. J Neurochem 121:680-692.
  12. Di Domenico F, Sultana R, Ferree A, Smith K, Barone E, Perluigi M, Coccia R, Pierce W, Cai J, Mancuso C, Squillace R, Wiengele M, Dalle-Donne I, Wolozin B, Butterfield DA (2012) Redox Proteomics Analyses of the Influence of Co-Expression of Wild-Type or Mutated LRRK2 and Tau on C. elegans Protein Expression and Oxidative Modification: Relevance to Parkinson Disease. Antioxid Redox Signal.
  13. Ding Q, Zhu H, Zhang B, Soriano A, Burns R, Markesbery WR (2012) Increased 5S rRNA Oxidation in Alzheimer's Disease. J Alzheimers Dis.
  14. Gleichmann M, Zhang Y, Wood WH, 3rd, Becker KG, Mughal MR, Pazin MJ, van Praag H, Kobilo T, Zonderman AB, Troncoso JC, Markesbery WR, Mattson MP (2012) Molecular changes in brain aging and Alzheimer's disease are mirrored in experimentally silenced cortical neuron networks. Neurobiol Aging 33:205 e201-218.
  15. Gold BT, Jiang Y, Powell DK, Smith CD (2012) Multimodal Imaging Evidence for Axonal and Myelin Deterioration in Amnestic Mild Cognitive Impairment. J Alzheimers Dis.
  16. Gold BT, Johnson NF, Powell DK, Smith CD (2012) White matter integrity and vulnerability to Alzheimer's disease: Preliminary findings and future directions. Biochim Biophys Acta 1822:416-422.
  17. Gwon AR, Park JS, Arumugam TV, Kwon YK, Chan SL, Kim SH, Baik SH, Yang S, Yun YK, Choi Y, Kim S, Tang SC, Hyun DH, Cheng A, Dann CE, 3rd, Bernier M, Lee J, Markesbery WR, Mattson MP, Jo DG (2012) Oxidative lipid modification of nicastrin enhances amyloidogenic gamma-secretase activity in Alzheimer's disease. Aging Cell.
  18. Holler CJ, Webb RL, Laux AL, Beckett TL, Niedowicz DM, Ahmed RR, Liu Y, Simmons CR, Dowling AL, Spinelli A, Khurgel M, Estus S, Head E, Hersh LB, Murphy MP (2012) BACE2 expression increases in human neurodegenerative disease. Am J Pathol 180:337-350.
  19. Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Thies B, Trojanowski JQ, Vinters HV, Montine TJ (2012) National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 8:1-13.
  20. Jicha GA, Abner EL, Schmitt FA, Kryscio RJ, Riley KP, Cooper GE, Stiles N, Mendiondo MS, Smith CD, Van Eldik LJ, Nelson PT (2012) Preclinical AD Workgroup staging: pathological correlates and potential challenges. Neurobiol Aging 33:622 e621-622 e616.
  21. Ling IF, Bhongsatiern J, Simpson JF, Fardo DW, Estus S (2012) Genetics of clusterin isoform expression and Alzheimer's disease risk. PLoS One 7:e33923.
  22. Migongo AW, Charnigo R, Love MM, Kryscio R, Fleming ST, Pearce KA (2012) Factors relating to patient visit time with a physician. Med Decis Making 32:93-104.
  23. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Trojanowski JQ, Vinters HV, Hyman BT (2012) National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol 123:1-11.
  24. Mufson EJ, Binder L, Counts SE, DeKosky ST, de Toledo-Morrell L, Ginsberg SD, Ikonomovic MD, Perez SE, Scheff SW (2012) Mild cognitive impairment: pathology and mechanisms. Acta Neuropathol 123:13-30.
  25. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, Castellani RJ, Crain BJ, Davies P, Del Tredici K, Duyckaerts C, Frosch MP, Haroutunian V, Hof PR, Hulette CM, Hyman BT, Iwatsubo T, Jellinger KA, Jicha GA, Kovari E, Kukull WA, Leverenz JB, Love S, Mackenzie IR, Mann DM, Masliah E, McKee AC, Montine TJ, Morris JC, Schneider JA, Sonnen JA, Thal DR, Trojanowski JQ, Troncoso JC, Wisniewski T, Woltjer RL, Beach TG (2012) Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 71:362-381.
  26. Schmitt FA, Nelson PT, Abner E, Scheff S, Jicha GA, Smith C, Cooper G, Mendiondo M, Danner DD, Van Eldik LJ, Caban-Holt A, Lovell MA, Kryscio RJ (2012) University of Kentucky Sanders-Brown Healthy Brain Aging Volunteers: Donor Characteristics, Procedures, and Neuropathology. Curr Alzheimer Res.
  27. Smith CD (2012) Structural imaging in early pre-states of dementia. Biochim Biophys Acta 1822:317-324.
  28. Smith CD, Andersen AH, Gold BT (2012) Structural Brain Alterations before Mild Cognitive Impairment in ADNI: Validation of Volume Loss in a Predefined Antero-Temporal Region. J Alzheimers Dis.
  29. Sudduth TL, Wilson JG, Everhart A, Colton CA, Wilcock DM (2012) Lithium treatment of APPSwDI/NOS2-/- mice leads to reduced hyperphosphorylated tau, increased amyloid deposition and altered inflammatory phenotype. PLoS One 7:e31993.
  30. Swerdlow RH, Jicha GA (2012) Alzheimer disease: Can the exam predict the pathology? Neurology.
  31. Wilcock DM (2012) Neuroinflammation in the aging down syndrome brain; lessons from Alzheimer's disease. Current gerontology and geriatrics research 2012:170276.
  32. Abner EL, Kryscio RJ, Schmitt FA, Santacruz KS, Jicha GA, Lin Y, Neltner JM, Smith CD, Van Eldik LJ, Nelson PT (2011) "End-stage" neurofibrillary tangle pathology in preclinical Alzheimer's disease: fact or fiction? J Alzheimers Dis 25:445-453.
  33. Abner EL, Schmitt FA, Mendiondo MS, Marcum JL, Kryscio RJ (2011) Vitamin E and all-cause mortality: a meta-analysis. Curr Aging Sci 4:158-170.
  34. Al-Sabbagh M, Alladah A, Lin Y, Kryscio RJ, Thomas MV, Ebersole JL, Miller CS (2011) Bone remodeling-associated salivary biomarker MIP-1alpha distinguishes periodontal disease from health. J Periodontal Res.
  35. Aluise CD, Robinson RA, Cai J, Pierce WM, Markesbery WR, Butterfield DA (2011) Redox proteomics analysis of brains from subjects with amnestic mild cognitive impairment compared to brains from subjects with preclinical Alzheimer's disease: insights into memory loss in MCI. J Alzheimers Dis 23:257-269.
  36. Alva G, Grossberg GT, Schmitt FA, Meng X, Olin JT (2011) Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. Int J Geriatr Psychiatry 26:356-363.
  37. Ansari MA, Scheff SW (2011) NADPH-oxidase activation and cognition in Alzheimer disease progression. Free Radic Biol Med 51:171-178.
  38. Bachstetter AD, Xing B, de Almeida L, Dimayuga ER, Watterson DM, Van Eldik LJ (2011) Microglial p38alpha MAPK is a key regulator of proinflammatory cytokine up-regulation induced by toll-like receptor (TLR) ligands or beta-amyloid (Abeta). J Neuroinflammation 8:79.
  39. Barone E, Cenini G, Di Domenico F, Martin S, Sultana R, Mancuso C, Murphy MP, Head E, Butterfield DA (2011) Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: a novel mechanism of action. Pharmacol Res 63:172-180.
  40. Barone E, Di Domenico F, Cenini G, Sultana R, Cini C, Preziosi P, Perluigi M, Mancuso C, Butterfield DA (2011) Biliverdin reductase--a protein levels and activity in the brains of subjects with Alzheimer disease and mild cognitive impairment. Biochim Biophys Acta 1812:480-487.
  41. Barone E, Di Domenico F, Cenini G, Sultana R, Coccia R, Preziosi P, Perluigi M, Mancuso C, Butterfield DA (2011) Oxidative and nitrosative modifications of biliverdin reductase-A in the brain of subjects with Alzheimer's disease and amnestic mild cognitive impairment. J Alzheimers Dis 25:623-633.
  42. Blalock EM, Buechel HM, Popovic J, Geddes JW, Landfield PW (2011) Microarray analyses of laser-captured hippocampus reveal distinct gray and white matter signatures associated with incipient Alzheimer's disease. J Chem Neuroanat 42:118-126.
  43. Blonder LX, Slevin JT (2011) Emotional dysfunction in Parkinson's disease. Behavioural neurology 24:201-217.
  44. Burchett ME, Ling IF, Estus S (2011) FBN1 isoform expression varies in a tissue and development-specific fashion. Biochem Biophys Res Commun 411:323-328.
  45. Butterfield DA (2011) Atorvastatin and Abeta(1-40): not as simple as cholesterol reduction in brain and relevance to Alzheimer disease. Exp Neurol 228:15-18.
  46. Butterfield DA (2011) Oxidative stress in Alzheimer disease: synergy between the Butterfield and Markesbery laboratories. Neuromolecular Med 13:19-22.
  47. Butterfield DA (2011) Preface for the special issue of neuromolecular medicine in memory of the life and legacy of William R. Markesbery, M.D. Neuromolecular Med 13:1-2.
  48. Butterfield DA, Barone E, Di Domenico F, Cenini G, Sultana R, Murphy MP, Mancuso C, Head E (2011) Atorvastatin treatment in a dog preclinical model of Alzheimer's disease leads to up-regulation of haem oxygenase-1 and is associated with reduced oxidative stress in brain. Int J Neuropsychopharmacol 1-7.
  49. Butterfield DA, Barone E, Mancuso C (2011) Cholesterol-independent neuroprotective and neurotoxic activities of statins: perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders. Pharmacol Res 64:180-186.
  50. Butterfield DA, Owen JB (2011) Lectin-affinity chromatography brain glycoproteomics and Alzheimer disease: insights into protein alterations consistent with the pathology and progression of this dementing disorder. Proteomics Clin Appl 5:50-56.
  51. Danner D, Thomason PC (2011) William R. Markesbery, MD: A 7th generation Kentuckian. Neuromolecular Med 13:17-18.
  52. Darnell KR, McGuire C, Danner DD (2011) African American participation in Alzheimer's disease research that includes brain donation. Am J Alzheimers Dis Other Demen 26:469-476.
  53. Di Domenico F, Sultana R, Barone E, Perluigi M, Cini C, Mancuso C, Cai J, Pierce WM, Butterfield DA (2011) Quantitative proteomics analysis of phosphorylated proteins in the hippocampus of Alzheimer's disease subjects. J Proteomics 74:1091-1103.
  54. Espinosa PS, Perez DL, Abner E, Ryan M (2011) Association of antiepileptic drugs, vitamin D, and calcium supplementation with bone fracture occurrence in epilepsy patients. Clinical neurology and neurosurgery 113:548-551.
  55. Ferris SH, Schmitt FA, Saxton J, Richardson S, Mackell J, Sun Y, Xu Y (2011) Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease. Alzheimers Res Ther 3:22.
  56. Geekiyanage H, Jicha GA, Nelson PT, Chan C (2011) Blood serum miRNA: Non-invasive biomarkers for Alzheimer's disease. Exp Neurol.
  57. Guttmann RP, Ghoshal S (2011) Thiol-protease oxidation in age-related neuropathology. Free Radic Biol Med 51:282-288.
  58. Head E (2011) Neurobiology of the aging dog. Age (Dordr) 33:485-496.
  59. Hebert SS, Nelson PT (2011) Studying microRNAs in the brain: Technical lessons learned from the first ten years. Exp Neurol.
  60. Hunter MP, Nelson M, Kurzer M, Wang X, Kryscio RJ, Head E, Pinna G, O'Bryan JP (2011) Intersectin 1 contributes to phenotypes in vivo: implications for Down's syndrome. Neuroreport 22:767-772.
  61. Ivanchak N, Abner EL, Carr SA, Freeman SJ, Seybert A, Ranseen J, Jicha GA (2011) Attention-deficit/hyperactivity disorder in childhood is associated with cognitive test profiles in the geriatric population but not with mild cognitive impairment or Alzheimer's disease. J Aging Res 2011:729801.
  62. Jicha GA (2011) Medical management of frontotemporal dementias: the importance of the caregiver in symptom assessment and guidance of treatment strategies. J Mol Neurosci 45:713-723.
  63. Jicha GA, Nelson PT (2011) Management of frontotemporal dementia: targeting symptom management in such a heterogeneous disease requires a wide range of therapeutic options. Neurodegener Dis Manag 1:141-156.
  64. Kasarskis EJ, Mendiondo MS, Wells S, Malguizo MS, Thompson M, Healey M, Kryscio RJ (2011) The ALS Nutrition/NIPPV Study: design, feasibility, and initial results. Amyotroph Lateral Scler 12:17-25.
  65. Keeney JT, Swomley AM, Harris JL, Fiorini A, Mitov MI, Perluigi M, Sultana R, Butterfield DA (2011) Cell Cycle Proteins in Brain in Mild Cognitive Impairment: Insights into Progression to Alzheimer Disease. Neurotox Res.
  66. Kramer PL, Xu H, Woltjer RL, Westaway SK, Clark D, Erten-Lyons D, Kaye JA, Welsh-Bohmer KA, Troncoso JC, Markesbery WR, Petersen RC, Turner RS, Kukull WA, Bennett DA, Galasko D, Morris JC, Ott J (2011) Alzheimer disease pathology in cognitively healthy elderly: a genome-wide study. Neurobiol Aging 32:2113-2122.
  67. Lovell MA (2011) Memories of Dr. William R. Markesbery. Neuromolecular Med 13:15-16.
  68. Lovell MA, Soman S, Bradley MA (2011) Oxidatively modified nucleic acids in preclinical Alzheimer's disease (PCAD) brain. Mech Ageing Dev 132:443-448.
  69. Martin SB, Cenini G, Barone E, Dowling AL, Mancuso C, Butterfield DA, Murphy MP, Head E (2011) Coenzyme Q10 and cognition in atorvastatin treated dogs. Neurosci Lett 501:92-95.
  70. Martin SB, Dowling AL, Head E (2011) Therapeutic interventions targeting Beta amyloid pathogenesis in an aging dog model. Current neuropharmacology 9:651-661.
  71. Mitchell MD, Mannino DM, Steinke DT, Kryscio RJ, Bush HM, Crofford LJ (2011) Association of smoking and chronic pain syndromes in Kentucky women. J Pain 12:892-899.
  72. Mohmmad Abdul H, Baig I, Levine H, 3rd, Guttmann RP, Norris CM (2011) Proteolysis of calcineurin is increased in human hippocampus during mild cognitive impairment and is stimulated by oligomeric Abeta in primary cell culture. Aging Cell 10:103-113.
  73. Murphy MP, Morales J, Beckett TL, Astarita G, Piomelli D, Weidner A, Studzinski CM, Dowling AL, Wang X, Levine H, 3rd, Kryscio RJ, Lin Y, Barrett E, Head E (2011) Changes in cognition and amyloid-beta processing with long term cholesterol reduction using atorvastatin in aged dogs. J Alzheimers Dis 22:135-150.
  74. Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK, Larson EB, Bird TD, Boeve BF, Graff-Radford NR, De Jager PL, Evans D, Schneider JA, Carrasquillo MM, Ertekin-Taner N, Younkin SG, Cruchaga C, Kauwe JS, Nowotny P, Kramer P, Hardy J, Huentelman MJ, Myers AJ, Barmada MM, Demirci FY, Baldwin CT, Green RC, Rogaeva E, St George-Hyslop P, Arnold SE, Barber R, Beach T, Bigio EH, Bowen JD, Boxer A, Burke JR, Cairns NJ, Carlson CS, Carney RM, Carroll SL, Chui HC, Clark DG, Corneveaux J, Cotman CW, Cummings JL, DeCarli C, DeKosky ST, Diaz-Arrastia R, Dick M, Dickson DW, Ellis WG, Faber KM, Fallon KB, Farlow MR, Ferris S, Frosch MP, Galasko DR, Ganguli M, Gearing M, Geschwind DH, Ghetti B, Gilbert JR, Gilman S, Giordani B, Glass JD, Growdon JH, Hamilton RL, Harrell LE, Head E, Honig LS, Hulette CM, Hyman BT, Jicha GA, Jin LW, Johnson N, Karlawish J, Karydas A, Kaye JA, Kim R, Koo EH, Kowall NW, Lah JJ, Levey AI, Lieberman AP, Lopez OL, Mack WJ, Marson DC, Martiniuk F, Mash DC, Masliah E, McCormick WC, McCurry SM, McDavid AN, McKee AC, Mesulam M, Miller BL, Miller CA, Miller JW, Parisi JE, Perl DP, Peskind E, Petersen RC, Poon WW, Quinn JF, Rajbhandary RA, Raskind M, Reisberg B, Ringman JM, Roberson ED, Rosenberg RN, Sano M, Schneider LS, Seeley W, Shelanski ML, Slifer MA, Smith CD, Sonnen JA, Spina S, Stern RA, Tanzi RE, Trojanowski JQ, Troncoso JC, Van Deerlin VM, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Williamson J, Woltjer RL, Cantwell LB, Dombroski BA, Beekly D, Lunetta KL, Martin ER, Kamboh MI, Saykin AJ, Reiman EM, Bennett DA, Morris JC, Montine TJ, Goate AM, Blacker D, Tsuang DW, Hakonarson H, Kukull WA, Foroud TM, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD (2011) Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 43:436-441.
  75. Nelson PT, Head E, Schmitt FA, Davis PR, Neltner JH, Jicha GA, Abner EL, Smith CD, Van Eldik LJ, Kryscio RJ, Scheff SW (2011) Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies. Acta Neuropathol 121:571-587.
  76. Nelson PT, Schmitt FA, Lin Y, Abner EL, Jicha GA, Patel E, Thomason PC, Neltner JH, Smith CD, Santacruz KS, Sonnen JA, Poon LW, Gearing M, Green RC, Woodard JL, Van Eldik LJ, Kryscio RJ (2011) Hippocampal sclerosis in advanced age: clinical and pathological features. Brain 134:1506-1518.
  77. Nelson PT, Wang WX, Mao G, Wilfred BR, Xie K, Jennings MH, Gao Z, Wang X (2011) Specific sequence determinants of miR-15/107 microRNA gene group targets. Nucleic Acids Res 39:8163-8172.
  78. Pietrzak M, Rempala G, Nelson PT, Zheng JJ, Hetman M (2011) Epigenetic silencing of nucleolar rRNA genes in Alzheimer's disease. PLoS One 6:e22585.
  79. Rapoport SI, Nelson PT (2011) Biomarkers and evolution in Alzheimer disease. Prog Neurobiol 95:510-513.
  80. Richert ND, Kryscio RJ (2011) Does one guideline fit all? Neurology 77:2080-2081.
  81. Riley KP, Jicha GA, Davis D, Abner EL, Cooper GE, Stiles N, Smith CD, Kryscio RJ, Nelson PT, Van Eldik LJ, Schmitt FA (2011) Prediction of preclinical Alzheimer's disease: longitudinal rates of change in cognition. J Alzheimers Dis 25:707-717.
  82. Ryou C, Titlow WB, Mays CE, Bae Y, Kim S (2011) The suppression of prion propagation using poly-L-lysine by targeting plasminogen that stimulates prion protein conversion. Biomaterials 32:3141-3149.
  83. Saijo E, Scheff SW, Telling GC (2011) Unaltered prion protein expression in Alzheimer disease patients. Prion 5:109-116.
  84. SantaCruz KS, Sonnen JA, Pezhouh MK, Desrosiers MF, Nelson PT, Tyas SL (2011) Alzheimer disease pathology in subjects without dementia in 2 studies of aging: the Nun Study and the Adult Changes in Thought Study. J Neuropathol Exp Neurol 70:832-840.
  85. Scheff SW (2011) William R. Markesbery, M.D.: mentor and friend. Neuromolecular Med 13:3-5.
  86. Scheff SW, Price DA, Schmitt FA, Scheff MA, Mufson EJ (2011) Synaptic loss in the inferior temporal gyrus in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 24:547-557.
  87. Segerstrom SC, Stanton AL, Flynn SM, Roach AR, Testa JJ, Hardy JK (2011) Episodic repetitive thought: dimensions, correlates, and consequences. Anxiety Stress Coping 25:3-21.
  88. Sexton WM, Lin Y, Kryscio RJ, Dawson DR, 3rd, Ebersole JL, Miller CS (2011) Salivary biomarkers of periodontal disease in response to treatment. J Clin Periodontol 38:434-441.
  89. Simmons CR, Zou F, Younkin SG, Estus S (2011) Evaluation of the global association between cholesterol-associated polymorphisms and Alzheimer's disease suggests a role for rs3846662 and HMGCR splicing in disease risk. Mol Neurodegener 6:62.
  90. Simmons CR, Zou F, Younkin SG, Estus S (2011) Rheumatoid arthritis-associated polymorphisms are not protective against Alzheimer's disease. Mol Neurodegener 6:33.
  91. Smith CD (2011) Structural imaging in early pre-states of dementia. Biochim Biophys Acta.
  92. Sultana R, Mecocci P, Mangialasche F, Cecchetti R, Baglioni M, Butterfield DA (2011) Increased protein and lipid oxidative damage in mitochondria isolated from lymphocytes from patients with Alzheimer's disease: insights into the role of oxidative stress in Alzheimer's disease and initial investigations into a potential biomarker for this dementing disorder. J Alzheimers Dis 24:77-84.
  93. Sultana R, Robinson RA, Di Domenico F, Abdul HM, St Clair DK, Markesbery WR, Cai J, Pierce WM, Butterfield DA (2011) Proteomic identification of specifically carbonylated brain proteins in APP(NLh)/APP(NLh) x PS-1(P264L)/PS-1(P264L) human double mutant knock-in mice model of Alzheimer disease as a function of age. J Proteomics 74:2430-2440.
  94. Telling GC (2011) Transgenic mouse models and prion strains. Topics in current chemistry 305:79-99.
  95. Threlkeld ZD, Jicha GA, Smith CD, Gold BT (2011) Task deactivation reductions and atrophy within parietal default mode regions are overlapping but only weakly correlated in mild cognitive impairment. J Alzheimers Dis 27:415-427.
  96. Timmons MD, Bradley MA, Lovell MA, Lynn BC (2011) Procedure for the isolation of mitochondria, cytosolic and nuclear material from a single piece of neurological tissue for high-throughput mass spectral analysis. J Neurosci Methods 197:279-282.
  97. van Nagell JR, Jr., Miller RW, DeSimone CP, Ueland FR, Podzielinski I, Goodrich ST, Elder JW, Huang B, Kryscio RJ, Pavlik EJ (2011) Long-term survival of women with epithelial ovarian cancer detected by ultrasonographic screening. Obstet Gynecol 118:1212-1221.
  98. Wang WX, Huang Q, Hu Y, Stromberg AJ, Nelson PT (2011) Patterns of microRNA expression in normal and early Alzheimer's disease human temporal cortex: white matter versus gray matter. Acta Neuropathol 121:193-205.
  99. Weidner AM, Bradley MA, Beckett TL, Niedowicz DM, Dowling AL, Matveev SV, LeVine H, 3rd, Lovell MA, Murphy MP (2011) RNA oxidation adducts 8-OHG and 8-OHA change with Abeta42 levels in late-stage Alzheimer's disease. PLoS One 6:e24930.
  100. Wijsman EM, Pankratz ND, Choi Y, Rothstein JH, Faber KM, Cheng R, Lee JH, Bird TD, Bennett DA, Diaz-Arrastia R, Goate AM, Farlow M, Ghetti B, Sweet RA, Foroud TM, Mayeux R (2011) Genome-wide association of familial late-onset Alzheimer's disease replicates BIN1 and CLU and nominates CUGBP2 in interaction with APOE. PLoS Genet 7:e1001308.
  101. Wilcock DM, Morgan D, Gordon MN, Taylor TL, Ridnour LA, Wink DA, Colton CA (2011) Activation of matrix metalloproteinases following anti-Abeta immunotherapy; implications for microhemorrhage occurrence. J Neuroinflammation 8:115.
  102. Wilson RS, Barral S, Lee JH, Leurgans SE, Foroud TM, Sweet RA, Graff-Radford N, Bird TD, Mayeux R, Bennett DA (2011) Heritability of different forms of memory in the Late Onset Alzheimer's Disease Family Study. J Alzheimers Dis 23:249-255.
  103. Xing B, Bachstetter AD, Van Eldik LJ (2011) Microglial p38alpha MAPK is critical for LPS-induced neuron degeneration, through a mechanism involving TNFalpha. Mol Neurodegener 6:84.